Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Heart Rate Control in Sepsis
NCT05882708Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivabradine in sepsis (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: The difference of a reduction in heart rate at 96 hours, The difference in Mean Arterial Pressure at 96 hours and 4 more. Started Jun 2023; status: recruiting.
02
Drugs
ivabradine
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05882708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882708.